Clinical Trial Detail

NCT ID NCT02141542
Title Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors F. Stephen Hodi, MD
Indications

melanoma

Therapies

Tremelimumab

MEDI3617

Age Groups: adult

No variant requirements are available.